Richard Barohn
Richard Barohn
Prof of neurology university of missouri
Verified email at
Cited by
Cited by
Myasthenia gravis: recommendations for clinical research standards
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis ...
Neurology 55 (1), 16-23, 2000
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
IE Lundberg, A Tjärnlund, M Bottai, VP Werth, C Pilkington, M De Visser, ...
Arthritis & rheumatology 69 (12), 2271-2282, 2017
Mutations in Kir2. 1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome
NM Plaster, R Tawil, M Tristani-Firouzi, S Canún, S Bendahhou, ...
Cell 105 (4), 511-519, 2001
Randomized trial of thymectomy in myasthenia gravis
GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ...
New England Journal of Medicine 375 (6), 511-522, 2016
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
PH Gordon, DH Moore, RG Miller, JM Florence, JL Verheijde, C Doorish, ...
The Lancet Neurology 6 (12), 1045-1053, 2007
Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review)[RETIRED] Report of the Quality Standards Subcommittee of the American Academy of …
GS Gronseth, RJ Barohn
Neurology 55 (1), 7-15, 2000
Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria
RJ Barohn, JT Kissel, JR Warmolts, JR Mendell
Archives of neurology 46 (8), 878-884, 1989
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo‐phase trial
CV Oddis, AM Reed, R Aggarwal, LG Rider, DP Ascherman, ...
Arthritis & Rheumatism 65 (2), 314-324, 2013
Interferon‐α/β–mediated innate immune mechanisms in dermatomyositis
SA Greenberg, JL Pinkus, GS Pinkus, T Burleson, D Sanoudou, R Tawil, ...
Annals of Neurology: Official Journal of the American Neurological …, 2005
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
KR Wagner, JL Fleckenstein, AA Amato, RJ Barohn, K Bushby, ...
Annals of neurology 63 (5), 561-571, 2008
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind …
JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ...
The Lancet Neurology 16 (12), 976-986, 2017
Genome-wide analyses identify KIF5A as a novel ALS gene
A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ...
Neuron 97 (6), 1267-1288, 2018
Myasthenia gravis: recommendations for clinical research standards1
A Jaretzki, RJ Barohn, RM Ernstoff, HJ Kaminski, JC Keesey, AS Penn, ...
The Annals of thoracic surgery 70 (1), 327-334, 2000
Clinical spectrum of chronic acquired demyelinating polyneuropathies
DS Saperstein, JS Katz, AA Amato, RJ Barohn
Muscle & Nerve: Official Journal of the American Association of …, 2001
Ataluren treatment of patients with nonsense mutation dystrophinopathy
K Bushby, R Finkel, B Wong, R Barohn, C Campbell, GP Comi, ...
Muscle & nerve 50 (4), 477-487, 2014
Guillain-Barré syndrome and variants
MM Dimachkie, RJ Barohn
Neurologic clinics 31 (2), 491-510, 2013
Practice parameter: immunotherapy for Guillain–Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology
RAC Hughes, EFM Wijdicks, R Barohn, E Benson, DR Cornblath, ...
Neurology 61 (6), 736-740, 2003
Myasthenia gravis activities of daily living profile
GI Wolfe, L Herbelin, SP Nations, B Foster, WW Bryan, RJ Barohn
Neurology 52 (7), 1487-1487, 1999
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
CM McDonald, C Campbell, RE Torricelli, RS Finkel, KM Flanigan, ...
The Lancet 390 (10101), 1489-1498, 2017
A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis
RG Miller, JH Petajan, WW Bryan, C Armon, RJ Barohn, JC Goodpasture, ...
Annals of neurology 39 (2), 256-260, 1996
The system can't perform the operation now. Try again later.
Articles 1–20